ADAM-17 (TACE) and MMP inhibitor (Ki = 120 nM at ADAM-17). Sensitizes cancer stem cells to the lethal effects of 5-FU in vitro. Blocks shedding of TNF-α from cell membranes.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solubility||Soluble to 5 mg/ml in water and to 5 mg/ml in ethanol|
Preparing Stock Solutions
The following data is based on the product molecular weight 415.54. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.41 mL||12.03 mL||24.07 mL|
|5 mM||0.48 mL||2.41 mL||4.81 mL|
|10 mM||0.24 mL||1.2 mL||2.41 mL|
|50 mM||0.05 mL||0.24 mL||0.48 mL|
References are publications that support the products' biological activity.
Moss et al (2007) Fluorescent substrates for the proteinases ADAM17, ADAM10, ADAM8, and ADAM12 useful for high-throughput inhibitor screening. Anal.Biochem. 366 144 PMID: 17548045
Wang et al (2016) A disintegrin and metalloproteinase domain 17 regulates colorectal cancer stem cells and chemosensitivity via notch1 signaling. Stem Cells Transl.Med. 5 331 PMID: 26744411
If you know of a relevant reference for TAPI 2, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: TAPI 2, supplier, TAPI2, ADAM17, metalloproteases, MMPs, metalloproteinases, inhibits, inhibitors, adams, TNFa, TNFα, converting, enzyme, TACE, ADAMs, Matrix, Metalloprotease, ADAMs, Tocris Bioscience
Citations for TAPI 2
Citations are publications that use Tocris products.
Currently there are no citations for TAPI 2. Do you know of a great paper that uses TAPI 2 from Tocris? If so please let us know.
TAPI 2 Reviews
Average Rating:(Based on 0 Reviews)
Literature in this Area
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.